Market

Trump's 'Trump 2.0' approach to tariffs unleashes new uncertainties for Wall Street and corporate America. With higher duties, a broader range of consumer goods impacted, and unpredictable legal maneuvering, the economic effects of Trump's trade war 2.0 remain unclear.

Published on: February 04, 2025, 04:00 PM UTC

Ferrari stock (RACE) surges after Q4 earnings beat expectations, leading to upgraded 2025 guidance. Despite tariff concerns, Ferrari's exclusive clientele and strong demand insulate the company, resulting in an impressive EBITDA margin of 38.3% and a sold-out order book extending through 2026.

Published on: February 04, 2025, 04:00 PM UTC

US stocks mixed as China retaliates to Trump's tariffs, raising trade war concerns

Published on: February 04, 2025, 03:04 PM UTC

The market is volatile as investors try to gauge the impact of Trump's tariff policy. While some think the tariffs will be a short-lived step toward a negotiated settlement, others believe they could weigh on S&P 500 earnings growth. Only time will tell which scenario plays out.

Published on: February 04, 2025, 03:03 PM UTC

US stocks traded mixed on Tuesday as investors assessed China's immediate retaliation to US President Donald Trump's additional tariffs amid concerns about the risk of a trade war.

Published on: February 04, 2025, 03:02 PM UTC

Pfizer beats Q4 expectations, revenue up 7% to $63.6 billion in 2024. Forecasts headwinds with pipeline development, Medicare negotiations, and government actions.

Published on: February 04, 2025, 03:01 PM UTC

Another round of tariffs could make shoes and clothes more expensive

Published on: February 04, 2025, 03:01 PM UTC

Prices are likely to rise for American shoppers as President Trump shuts a trade loophole that has kept prices low at Shein, Temu, and Amazon Haul, with the impact expected to be particularly disruptive for small and medium-sized online retailers who source from China.

Published on: February 04, 2025, 03:00 PM UTC

Stock markets show little change as trade tensions persist; China retaliates with tariffs and initiates Google probe; Google and AMD to release earnings; Palantir surges on strong AI demand; PepsiCo disappoints with mixed results.

Published on: February 04, 2025, 02:07 PM UTC

Merck reported Q4 and full-year earnings in line with estimates. Sales rose 7% to $64.2 billion in 2024, while EPS was $7.65. However, the stock dropped 8% pre-market due to weaker-than-expected 2025 guidance, indicating only a slight increase in revenue compared to 2024. Analysts have raised concerns about Merck's pipeline and competition, while comparing it to Pfizer, which also reported earnings on Tuesday and showed positive long-term potential. Merck's key revenue drivers include Gardasil and Keytruda, but Gardasil has faced challenges in China and Keytruda's patent expires in 2028.

Published on: February 04, 2025, 02:05 PM UTC